Literature DB >> 222684

Evaluation of a ribosomal vaccine against pertussis.

L H Field, C D Parker, C R Manclark, L J Berry.   

Abstract

A crude ribosomal vaccine derived from Bordetella pertussis administered to ICR and N:NIH (SW) strains of mice protected them effectively against a standardized intracranial challenge. The dose of vaccine that protected half the mice was less for N:NIH (SW) than for ICR mice and compared favorably with a killed reference vaccine. Ribosomes prepared from bacteria ground with washed sea sand were more immunogenic than those obtained by rupture with alumina or with a Braun homogenizer. The protective effect of the crude ribosomes was not an innate part of the organelle but was due to a substance or substances that could be removed from them by a 1 M NH4Cl wash. The material in the wash was highly immunogenic and retained both the histamine-sensitizing and leukocytosis-promoting properties. It lost much of the dermonecrotic activity and was poorly pyrogenic in rabbits. The most potent pyrogen was present in the washed ribosomes, which apparently, retained the endotoxic components of the cell wall. The best vaccines permitted acceptable weight gain in the immunized mice.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 222684      PMCID: PMC414307          DOI: 10.1128/iai.24.2.346-351.1979

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  9 in total

1.  Biologically active components and properties of Bordetella pertussis.

Authors:  S I Morse
Journal:  Adv Appl Microbiol       Date:  1976       Impact factor: 5.086

2.  Pertussis outbreak in Austin and Travis County, Texas, 1975.

Authors:  L H Field; C D Parker
Journal:  J Clin Microbiol       Date:  1977-08       Impact factor: 5.948

3.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

4.  The current status of pertussis vaccine: an overview.

Authors:  C R Manclark
Journal:  Adv Appl Microbiol       Date:  1976       Impact factor: 5.086

5.  Evidence for an extrinsic immunogen in effective ribosomal vaccines from Salmonella typhimurium.

Authors:  P Hoops; N E Prather; J Berry; J M Ravel
Journal:  Infect Immun       Date:  1976-04       Impact factor: 3.441

6.  A simple chemically defined medium for the production of phase I Bordetella pertussis.

Authors:  D W Stainer; M J Scholte
Journal:  J Gen Microbiol       Date:  1970-10

7.  Assay of pertussis vaccine toxicity by a rat-paw-oedema method.

Authors:  C R Manclark; M A Urban; E P Summers; J H Vickers
Journal:  J Med Microbiol       Date:  1977-02       Impact factor: 2.472

8.  IMMUNOGENIC ACTIVITY OF A RIBOSOMAL FRACTION OBTAINED FROM MYCOBACTERIUM TUBERCULOSIS.

Authors:  A S YOUMANS; G P YOUMANS
Journal:  J Bacteriol       Date:  1965-05       Impact factor: 3.490

9.  Extracytoplasmic adenylate cyclase of Bordetella pertussis.

Authors:  E L Hewlett; M A Urban; C R Manclark; J Wolff
Journal:  Proc Natl Acad Sci U S A       Date:  1976-06       Impact factor: 11.205

  9 in total
  6 in total

1.  Ribonuclease-sensitive ribosomal vaccines.

Authors:  R Gonggrijp; A C Antonissen; J F van den Bosch; C P van Boven
Journal:  Antonie Van Leeuwenhoek       Date:  1984       Impact factor: 2.271

2.  Serotype-nonspecific protection induced by ribonucleic acid isolated from the ribosomal vaccine of Pseudomonas aeruginosa.

Authors:  R Gonggrijp; W J Mullers; C P van Boven
Journal:  Infect Immun       Date:  1981-07       Impact factor: 3.441

3.  Immunogenicity of transfer RNA isolated from a two-heptose rough mutant of Salmonella typhimurium LT2 in mouse typhoid infection.

Authors:  E Kita; S Kashiba
Journal:  Immunology       Date:  1983-11       Impact factor: 7.397

4.  Candida albicans-induced agglutinin and immunoglobulin E responses in mice.

Authors:  G E Winterrowd; J E Cutler
Journal:  Infect Immun       Date:  1983-07       Impact factor: 3.441

5.  Protective immunity against murine candidiasis elicited by Candida albicans ribosomal fractions.

Authors:  R Levy; E Segal; E Eylan
Journal:  Infect Immun       Date:  1981-03       Impact factor: 3.441

6.  Evidence for the presence of lipopolysaccharide in a ribonuclease-sensitive ribosomal vaccine of Pseudomonas aeruginosa.

Authors:  R Gonggrijp; M P Volleberg; P J Lemmens; C P van Boven
Journal:  Infect Immun       Date:  1981-03       Impact factor: 3.441

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.